Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Jeffrey

Showing results (591-600 of 651) with videos related to

Pageof 66
Sort By:
ACS Chemical Neuroscience|September 24, 2024
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)Julie L Engers, Logan A Baker, Sichen Chang, et al.
Molecular Pharmacology|July 31, 2008
Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4Colleen M Niswender, Kari A Johnson, C David Weaver, et al.
ACS Chemical Neuroscience|April 28, 2018
A Novel M<sub>1</sub> PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic ToxicityJerri M Rook, Jeanette L Bertron, Hyekyung P Cho, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2017
Challenges in the development of an M<sub>4</sub> PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amidesJames C Tarr, Michael R Wood, Meredith J Noetzel, et al.
ACS Chemical Neuroscience|December 22, 2016
Diverse Effects on M<sub>1</sub> Signaling and Adverse Effect Liability within a Series of M<sub>1</sub> Ago-PAMsJerri M Rook, Masahito Abe, Hyekyung P Cho, et al.
ACS Medicinal Chemistry Letters|July 16, 2025
Discovery of a Novel sp<sup>3</sup>‑Rich M<sub>1</sub> Positive Allosteric Modulators (PAMs) Chemotype via Scaffold HoppingJoseph D Bungard, Paul Spearing, Yu Nishio, et al.
ACS Chemical Neuroscience|April 15, 2016
Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)Darren W Engers, Anna L Blobaum, Rocco D Gogliotti, et al.
Biological Psychiatry|November 13, 2012
Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activityJerri M Rook, Meredith J Noetzel, Wendy A Pouliot, et al.
ACS Medicinal Chemistry Letters|August 20, 2021
Discovery of VU6028418: A Highly Selective and Orally Bioavailable M<sub>4</sub> Muscarinic Acetylcholine Receptor AntagonistMatthew Spock, Trever R Carter, Katrina A Bollinger, et al.
Leukemia|November 14, 2013
Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemiaM A Dawson, E J Gudgin, S J Horton, et al.
Pageof 66

Showing results (591-600 of 651) with videos related to

Sort By:
Pageof 66
ACS Chemical Neuroscience|September 24, 2024
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)Julie L Engers, Logan A Baker, Sichen Chang, et al.
Molecular Pharmacology|July 31, 2008
Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4Colleen M Niswender, Kari A Johnson, C David Weaver, et al.
ACS Chemical Neuroscience|April 28, 2018
A Novel M<sub>1</sub> PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic ToxicityJerri M Rook, Jeanette L Bertron, Hyekyung P Cho, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2017
Challenges in the development of an M<sub>4</sub> PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amidesJames C Tarr, Michael R Wood, Meredith J Noetzel, et al.
ACS Chemical Neuroscience|December 22, 2016
Diverse Effects on M<sub>1</sub> Signaling and Adverse Effect Liability within a Series of M<sub>1</sub> Ago-PAMsJerri M Rook, Masahito Abe, Hyekyung P Cho, et al.
ACS Medicinal Chemistry Letters|July 16, 2025
Discovery of a Novel sp<sup>3</sup>‑Rich M<sub>1</sub> Positive Allosteric Modulators (PAMs) Chemotype via Scaffold HoppingJoseph D Bungard, Paul Spearing, Yu Nishio, et al.
ACS Chemical Neuroscience|April 15, 2016
Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)Darren W Engers, Anna L Blobaum, Rocco D Gogliotti, et al.
Biological Psychiatry|November 13, 2012
Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activityJerri M Rook, Meredith J Noetzel, Wendy A Pouliot, et al.
ACS Medicinal Chemistry Letters|August 20, 2021
Discovery of VU6028418: A Highly Selective and Orally Bioavailable M<sub>4</sub> Muscarinic Acetylcholine Receptor AntagonistMatthew Spock, Trever R Carter, Katrina A Bollinger, et al.
Leukemia|November 14, 2013
Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemiaM A Dawson, E J Gudgin, S J Horton, et al.
Pageof 66